latest news in companies
FDA Grants Exclusive Market Status to OSE Immunotherapeutics for Heart Transplant Drug
Nantes, Monday, 27 April 2026.
The FDA has granted OSE Immunotherapeutics lucrative Orphan Drug Designation for its heart transplant treatment, unlocking seven years of potential market exclusivity and significant developmental tax incentives.
Novartis Secures Landmark European Approval for New Oral Skin Therapy
Basel, Monday, 27 April 2026.
Novartis secured European approval for Rhapsido, the first oral targeted therapy for chronic hives. Requiring no liver monitoring, this breakthrough safely unlocks a highly lucrative market for investors.
European Regulators Back Santhera's Expanded Muscular Dystrophy Treatment for Toddlers
Pratteln, Monday, 27 April 2026.
European regulators recommended expanding Santhera’s muscular dystrophy drug to children aged two and older. Notably, the therapy yields an 80% reduction in vertebral fractures compared to traditional treatments.
Vcitychain Activates High-Speed Blockchain Network to Drive Next-Generation Digital Economies
San Francisco, Monday, 27 April 2026.
Vcitychain’s newly launched blockchain network achieves lightning-fast, second-level transaction speeds. This major upgrade empowers users with direct voting control, setting a new standard for decentralized digital infrastructure.
Cross-Border Tech Alliance Accelerates the Global Rollout of Autonomous Vehicles
Amsterdam, Monday, 27 April 2026.
On April 27, 2026, HERE Technologies partnered with China’s neueHCT to deploy self-driving systems globally, bridging Chinese autonomous innovation with international markets like Europe and the Gulf.